title: Oxidized LDL induces an oxidative stress and activates the tumor suppressor p53 in MRC5 human fibroblasts.
abstract: It is now well established that oxidized LDL (OxLDL) is involved in the progression of the atheromatous plaque via several mechanisms, including its cytotoxicity toward the arterial wall. Our study demonstrates that a 4-h incubation of cultured human fibroblasts with 25-75 microg/ml OxLDL induced a dose-dependent increase in the intracellular levels of reactive oxygen species (ROS) and lipid peroxidation end products (TBARS). This effect was markedly prevented by the antioxidant vitamin E. The lipid extract of OxLDL partially reproduced the action of the LDL particle itself. Concomitantly, OxLDL enhanced the DNA binding activity of p53 measured by electrophoretic mobility shift assay, and the intracellular protein level of p53 determined by immunoblot analysis. Cycloheximide prevented the OxLDL-induced augmentation in both p53 binding activity and intracellular level. Again, the lipid extract of OxLDL reproduced the effect of OxLDL on p53 binding activity, whereas vitamin E prevented it. These results indicate that OxLDL initiates an intracellular oxidative stress by means of its lipid peroxidation products, leading to the activation of the tumour suppressor p53 by enhancement of p53 protein synthesis. This effect might be related to the cytotoxic effect of OxLDL since the activation of p53 is known to lead to cell cycle arrest, necrosis or apoptosis.
authors.affiliation: Laboratoire de Biochimie, Université de Picardie Jules Verne, CHRU d'Amiens, Place Victor Pauchet, Amiens Cedex 1, 80054, France. cmaziere@nnx.com
authors.forename: C
authors.initials: C
authors.lastname: Mazière
authors.forename: A
authors.initials: A
authors.lastname: Meignotte
authors.forename: F
authors.initials: F
authors.lastname: Dantin
authors.forename: M A
authors.initials: MA
authors.lastname: Conte
authors.forename: J C
authors.initials: JC
authors.lastname: Mazière
mesh_terms: D001665:Binding Sites / Q000187:drug effects; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005347:Fibroblasts / Q000187:drug effects* / Q000502:physiology; D016147:Genes, Tumor Suppressor / Q000502:physiology; D006801:Humans; D015227:Lipid Peroxidation; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D018384:Oxidative Stress / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism* / Q000502:physiology; D014810:Vitamin E / Q000494:pharmacology
chemical_list: D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D016159:Tumor Suppressor Protein p53; C099252:oxidized low density lipoprotein; D014810:Vitamin E; D004247:DNA; D003513:Cycloheximide